Syndax Pharmaceuticals
SNDX
246 hedge funds and large institutions have $2.32B invested in Syndax Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 99 increasing their positions, 68 reducing their positions, and 25 closing their positions.
86% more call options, than puts
Call options by funds: $15.2M | Put options by funds: $8.14M
80% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 25
46% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 68
11% more capital invested
Capital invested by funds: $2.1B → $2.32B (+$222M)
7% more funds holding
Funds holding: 229 → 246 (+17)
2.28% less ownership
Funds ownership: 114.94% → 112.66% (-2.3%)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$82.1M |
| 2 |
O
OrbiMed
New York
|
+$20.9M |
| 3 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$15.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.71M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$62.9M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$26M |
| 3 |
Goldman Sachs
New York
|
-$15.2M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$14.2M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$13.2M |
SNDX Hedge Fund Activity: Q1 2026 in Review
246 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2026, worth a combined $2.32B — up 11% from $2.1B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new SNDX positions and 25 closed out — a net gain of 20 holders — while 99 added to existing stakes and 68 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $82.1M. The largest seller was Point72 Asset Management, cutting an estimated $62.9M.
- 246 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2026, up from 229 in Q4 2025.
- Funds reported $2.32B of Syndax Pharmaceuticals stock for Q1 2026, up 11% quarter-over-quarter.
- 45 funds opened new Syndax Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +20 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2026 was Deerfield Management, an estimated $82.1M added.
- The largest Syndax Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $62.9M sold.
Based on aggregated 13F filings for Q1 2026.